Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Clot-Busting’ at Stroke Site is Viable Option

22.06.2004


A small Ohio study has offered the first published evidence that aggressively treating brain blood clots at their source soon after symptoms start can produce a good outcome for many stroke patients.



In the study, published in a recent issue of the journal Neurosurgery, 50 percent of stroke patients had little or no neurological disability one to three months after clot-dissolving medication was delivered directly to the site of the blockages, compared to 39 percent of patients with similarly good outcomes documented in a large national trial of intravenous (IV) drug treatment for stroke. In all cases, time was an issue: The drugs in both trials were administered within three hours of the onset of symptoms.

“The results tell us what many of us suspected – that targeting the problem and delivering drugs right to the problem is a better option for appropriate stroke patients,” said Eric Bourekas, an interventional neuroradiologist at Ohio State University Medical Center and lead author of the study.


Researchers at OSU Medical Center and Case Western Reserve University compared patient outcomes from their institutions to the outcomes reported in 1995 after a study led by the National Institute of Neurological Disorders and Stroke. In that large trial, patients who were treated intravenously with recombinant tissue plasminogen activator (rt-PA) within three hours of symptom onset were at least 30 percent more likely to have good outcomes compared to patients on placebo. That study led to the intravenous use of rt-PA as the only federally approved clot-dissolving treatment of ischemic stroke – the roughly 80 percent of strokes caused by blockage of a blood vessel.

The two Ohio centers treated hundreds of stroke patients using the intra-arterial (IA) method of drug delivery over the time period observed, between 1993 and 2002, but only 36 patients received the medication within three hours after symptoms began, matching the conditions of therapy measured in the NINDS trial. These patients also had the same median admission score – based on a common stroke severity analysis tool – as the NINDS patients.

The intra-arterial treatment involves first obtaining X-rays of the affected blood vessels, or angiograms, by introducing a contrast agent to the bloodstream. Once the blockage is identified, physicians insert a catheter in the leg that is guided through the neck to the brain and the site of the clot. Physicians at OSU and CWRU used a different clot-dissolving agent, urokinase, until it became unavailable in the United States, and then began using rt-PA, the approved drug for IV use in stroke patients. Physicians stopped administering the drug either once the vessel completely opened or when the maximum drug dose was reached.

“Based on its symptoms, stroke can look like something else, so an advantage of the IA therapy is that we are much more clear about what we’re treating. We study the blood vessels, we see the clot, we know we’re treating a stroke, and the level of confidence is much higher,” Bourekas said. “We also may use less of the drug, which may reduce the risk of hemorrhage, because we can watch the clot dissolve and stop administering the drug as soon as the vessel opens up.”

The biggest advantage demonstrated by the study is that administering drugs at the clot site rather than through an IV is more likely to reopen the vessel, considered a major contributor to improved stroke outcomes. Partial or complete recanalization occurred in 75 percent of the patients treated with IA therapy at OSU and Case Western, compared to the 20 percent-to-50 percent range of recanalization in most IV treatment trials, said Andrew Slivka, a study co-author, neurologist and director of OSU Medical Center’s stroke division.

The rates of patient deaths and symptomatic hemorrhages were comparable to rates in other stroke studies, and tended to be associated strongly with much more severe strokes rather than treatment method. Angiography and catheterization of blood vessels in the head do carry risks, but the Ohio study resulted in only one catheterization-related complication that did not cause neurological damage, the researchers said.

Having a 24-hour stroke treatment center is required to achieve the best results with the intra-arterial therapy, the Ohio State researchers noted. “A team of radiologists and neurologists must be available around the clock and be ready for that rapid response,” Slivka said. “When blood flow to the brain is compromised, the brain won’t tolerate it for very long. Time is critical. The faster we can dissolve the clot to re-establish blood flow to that part of the brain, the more likely we are to have a good result.”

Patients’ realization that they’re having a stroke and their ability to get to a hospital are major variables, as well. Major stroke symptoms include a sudden inability to move a leg or arm, slurred speech or being unable to talk, sudden blindness, a sudden headache or numbness throughout one side of the body.

Finally, the researchers acknowledge they cannot recommend IA therapy across the board given the small size of their study. Bourekas said a larger study is needed to prove that “clot-busting” at the stroke site offers better chances for a good stroke outcome than IV therapy, and said researchers are hopeful a large, federal trial will be done to further test the therapy’s effectiveness.

Additional study co-authors were Rajul Shah of OSU Medical Center and Robert Tarr, Jeffrey Sunshine and Jose Suarez of the University Hospitals of Cleveland and CWRU.

OSU | newswise
Further information:
http://www.osu.edu

More articles from Studies and Analyses:

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

nachricht Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Solar Collectors from Ultra-High Performance Concrete Combine Energy Efficiency and Aesthetics

16.01.2017 | Trade Fair News

3D scans for the automotive industry

16.01.2017 | Automotive Engineering

Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs

16.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>